Ivosidenib, an oral IDH1 inhibitor, has been studied in a phase III clinical trial (ClarIDHy) for patients with pretreated IDH1 mutant cholangiocarcinoma. The gene discussed is IDH1; the disease is cholangiocarcinoma.